With recent clinical updates from Pfizer, Sarepta and Audenteson their programs in muscular disorders, the timely Gene Therapy for Muscular Disorders arrives as the only meeting dedicated to overcoming the translational […]
Update on Pfizer’s Duchenne gene therapy Phase 3 clinical program In line with our continued efforts to work with the Duchenne community and share information as it becomes available, we […]
Results suggest a highly potent next-generation treatment that could offer greater efficacy with less frequent dosing SRP-5051 dosed monthly at 30 mg/kg delivered mean exon skipping of 10.79% and mean dystrophin […]
Join us for a presentation on the clinical development process behind approved therapies and the importance of dose and administration of corticosteroids by Dr. Emma Ciafaloni. This presentation will be […]
Today, CureDuchenne Ventures is pleased to share that we made a research investment into Code BioTherapeutics and their next-generation gene therapy platform. This is a promising technology aimed at overcoming […]
Webinar Information PepGen presents an overview of its enhanced delivery oligonucleotide platform and how this innovative platform technology is being applied to create a transformative exon skipping therapy. James McArthur, […]
Built by the community, for the community, the DuchenneXchange has offered a secure place to inform, inspire and empower those living with Duchenne since its inception in 2018. By offering […]
CureDuchenne continued funding a robust Duchenne drug development pipeline with a new investment in Entrada Therapeutics as part of their latest financing from a group of investors. Entrada Therapeutics’ promising […]
This webinar covers the following topics: Understanding the Clinical Trial Process Managing Expectations Featured Speakers: Ana Christensen, MPH – TRiNDS and Italfarmaco Leslie Porter – Family, Duchenne Advocate Michael Kelly, […]
